The Endpoints Slack interview: Cellino CEO Nabiha Saklayen on cell therapy’s future, Elon Musk and time travel

Nabiha Saklayen founded Cellino Biotech just as she was finishing her PhD in physics at Harvard in 2017, while she was still in her 20s.

The startup is trying to create automated ways to produce cell therapies and raised an $80 million Series A round in 2022 to get to work. Endpoints News caught up with Saklayen on how that effort is going, as well as her thoughts on Elon Musk, mission control at Cellino, and even time travel.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

A nonprofit does deals in Brazil and India to make low-cost CAR-T cell therapies widely available

In the latest bid to widen access to medicines, a nonprofit is sending technology and materials for making expensive CAR-T cell therapies to the Brazilian

May 8, 2024

Special report 2024: Meet 20 women breaking new ground in biopharma R&D

Dedicated to the memory of Natalie Grover, who co-created the Women in Biopharma R&D special report while she was a reporter at Endpoints from 2018-2020.

October 8, 2024

Large Study Eases Fears Over Zantac-Cancer Link

People who took ranitidine (Zantac) for at least a month were no more likely to develop cancer than people who used other histamine-2 receptor antagonists

September 20, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.